Your new experience awaits. Try the new design now and help us make it even better

TECHNOLOGY AND CODE article

Front. Bioinform.

Sec. Protein Bioinformatics

Volume 5 - 2025 | doi: 10.3389/fbinf.2025.1576317

Protein Cleaver: An interactive web interface for in silico prediction and systematic annotation of protein digestion-derived peptides

Provisionally accepted
  • 1Pfizer, Thessaloniki, Greece
  • 2Pfizer, Groton, Connecticut, United States

The final, formatted version of the article will be published soon.

Proteolytic digestion is an essential process in mass spectrometry-based proteomics for converting proteins into peptides, hence crucial for protein identification and quantification. In a typical proteomics experiment, digestion reagents are selected without prior evaluation of their optimality for detecting proteins or peptides of interest, partly due to the lack of comprehensive and user-friendly predictive tools. In this work, we introduce Protein Cleaver, a web-based application that systematically assesses regions of proteins that are likely or unlikely to be identified, along with extensive sequence and structure annotation and visualization features. We showcase practical examples of Protein Cleaver's usability in drug discovery and highlight proteins that are typically difficult to detect using the most common proteolytic enzymes. We evaluate trypsin and chymotrypsin for identifying G-protein-coupled receptors and discover that chymotrypsin produces significantly more identifiable peptides than trypsin. We perform a bulk digestion analysis and assess 36 proteolytic enzymes for their ability to detect most of cysteine-containing peptides in the human proteome. We anticipate Protein Cleaver to be a valuable auxiliary tool for proteomics scientists.

Keywords: Proteolytic digestion, peptide annotation, Peptide identification, Mass Spectrometry, Proteomics

Received: 14 Feb 2025; Accepted: 11 Aug 2025.

Copyright: © 2025 Koulouras and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Grigorios Koulouras, Pfizer, Thessaloniki, Greece

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.